<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source></source><date>Sat Feb 27 04:03:34 EST 2016</date><key></key>
<document><id>19302901</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Monitoring patients for adverse events, the need for dose adjustments, or both during coadministration with posaconazole may be warranted in patients being treated with benzodiazepines that are predominantly metabolized through CYP3A4 (eg, midazolam).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="108" length="12"/><text>posaconazole</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="240" length="9"/><text>midazolam</text></annotation></passage></document>
<document><id>19475309</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: High clonidine dose (75 microg) associated to hyperbaric bupivacaine during high-level spinal anesthesia (T4) induces a higher incidence of arterial hypotension but prolongs sensory block and postoperative analgesia similar to lower clonidine dose (45 microg) during upper spinal anesthesia.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="246" length="9"/><text>clonidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="70" length="11"/><text>bupivacaine</text></annotation></passage></document>
<document><id>23600442</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Examining the details of the temporal features of the evoked profiles reveals no clear evidence for long-distance diffusion of dopamine between fast and slow domains, even though uptake inhibition by nomifensine clearly prolongs the time that dopamine resides in the extracellular space.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="200" length="11"/><text>nomifensine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="243" length="8"/><text>dopamine</text></annotation></passage></document>
<document><id>22473025</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Chlordiazepoxide produced significant decreases in food-maintained responding and the dose of ethanol presented, but only at the highest dose tested.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="16"/><text>chlordiazepoxide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="94" length="7"/><text>ethanol</text></annotation></passage></document>
<document><id>19952329</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: The combination of chronic amiodarone and acute ranolazine produces a synergistic use-dependent depression of I(Na)-dependent parameters in isolated canine atria, leading to a potent effect of the drug combination to prevent the induction of atrial fibrillation.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="40" length="10"/><text>amiodarone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="61" length="10"/><text>ranolazine</text></annotation></passage></document>
<document><id>21457221</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="69" length="7"/><text>aspirin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="80" length="9"/><text>rofecoxib</text></annotation></passage></document>
<document><id>20568489</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Several drugs, including sucralfate, acarbose, cytotoxic agents, and enzyme inducers, can reduce digoxin plasma concentrations.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="37" length="8"/><text>acarbose</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="97" length="7"/><text>digoxin</text></annotation></passage></document>
<document><id>22853551</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS AND POTENTIAL RELEVANCE: A dexmedetomidine CRI at the reported dose significantly reduces the MAC of sevoflurane.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="39" length="15"/><text>dexmedetomidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="113" length="11"/><text>sevoflurane</text></annotation></passage></document>
<document><id>23056363</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Our results indicate that modafinil can interfere with methamphetamine actions and provide protection against dopamine toxicity, cell death, and neuroinflammation in the mouse striatum.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="26" length="9"/><text>modafinil</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="55" length="15"/><text>methamphetamine</text></annotation></passage></document>
<document><id>21532183</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>METHODS AND RESULTS: Pravastatin (112 nmol/L) pretreatment for 60 min reduced both the potency and maximal constrictor responses to phenylephrine, thromboxane (U46619) and serotonin in small vessels.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="21" length="11"/><text>pravastatin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="132" length="13"/><text>phenylephrine</text></annotation></passage></document>
<document><id>20868607</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Ketamine can remarkably inhibit calcium currents in the central neurons,which may explain at least partly the action of ketamine on central nervous system.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="44" length="7"/><text>calcium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="132" length="8"/><text>ketamine</text></annotation></passage></document>
<document><id>19935588</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Thus, the vasodilative, antianginal and antiarrhythmic actions of amiodarone may be further enhanced by the simultaneous supplementation of calcium channel blockers via synergistic mechanisms, supporting the clinical use of such drug combinations.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="66" length="10"/><text>amiodarone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="140" length="24"/><text>calcium channel blockers</text></annotation></passage></document>
<document><id>19318402</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We propose that earlier introduction of rituximab may reduce the side effects related to other cytotoxic therapy mainly steroids and cyclophosphamide.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="40" length="9"/><text>rituximab</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="133" length="16"/><text>cyclophosphamide</text></annotation></passage></document>
<document><id>22229510</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Addition of L-NAME (10?4 M) resulted in full recovery of the responses to phenylephrine in SMA bed, while aminoguanidine (AG, 10?4 M) caused only partial recovery.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="12" length="6"/><text>L-NAME</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="74" length="13"/><text>phenylephrine</text></annotation></passage></document>
<document><id>20650241</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Cyproheptadine blocks all transformations with progesterone or HO-progesterone as starting point.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="14"/><text>cyproheptadine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="66" length="12"/><text>progesterone</text></annotation></passage></document>
<document><id>21623581</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Cinacalcet, for example, is a drug that allosterically modifies the receptor so as to increase its sensitivity to circulating calcium (thus the name "calcimimetic") and in this way decreases parathyroid hormone secretion.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="10"/><text>cinacalcet</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="126" length="7"/><text>calcium</text></annotation></passage></document>
<document><id>19816075</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Supplementation with folic acid and vitamin B12 during treatment with pemetrexed is recommended to reduce potential haematological and gastrointestinal adverse events.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="21" length="5"/><text>folic</text></annotation></passage></document>
<document><id>21952292</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Conclusion: Etanercept and anakinra efficiently and dose-dependently prevent cytokine-induced bone growth impairment, and combination with IGF-I further improves bone growth.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="12" length="10"/><text>etanercept</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="27" length="8"/><text>anakinra</text></annotation></passage></document>
<document><id>20021043</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Pretreatment with the poly (ADP-ribose) polymerase (PARP) inhibitor nicotinamide was able to prevent HCN2 cell death.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="22" length="28"/><text>poly (ADP-ribose) polymerase</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="68" length="12"/><text>nicotinamide</text></annotation></passage></document>
<document><id>19066411</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We demonstrated that low, ineffective doses of NMDA antagonists (the competitive NMDA antagonist CGP 37849, 0.3 mg/kg; an antagonist of the glycineB sites, L-701,324, 1 mg/kg; a partial agonist of the glycineB sites, D-cycloserine, 2.5 mg/kg; and the non-competitive NMDA antagonist MK-801, 0.05 mg/kg) administered together with an ineffective dose of magnesium (10 mg/kg) evoked a significant increase in the percentage of time spent in the open arm of the maze (an index of anxiety).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="217" length="11"/><text>cycloserine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="353" length="9"/><text>magnesium</text></annotation></passage></document>
<document><id>19942153</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Many commonly used drugs, such as bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="157" length="10"/><text>raloxifene</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="253" length="13"/><text>levothyroxine</text></annotation></passage></document>
<document><id>19426743</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>It was recently shown that the benzoxaborole antifungal compound AN2690 (5-fluoro-1,3-dihydro-1-hydroxy-1,2-benzoxaborole) inhibits LeuRS by forming a covalent adduct with the 3' adenosine of tRNA(leu) at the editing site, thus locking the enzyme in an inactive conformation.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="65" length="6"/><text>an2690</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="132" length="5"/><text>LeuRS</text></annotation></passage></document>
<document><id>23364964</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We co-administered carbidopa with levodopa to prevent peripheral synthesis of dopamine from levodopa, and observed tactile, cold, and heat allodynia pre-administration, and at 15, 30, 60, 90, 120, 150, 180, and 240 min after drug administration.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="19" length="9"/><text>carbidopa</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="34" length="8"/><text>levodopa</text></annotation></passage></document>
<document><id>20207521</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Topiramate could prevent olanzapine induced weight gain and adverse metabolic effects.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="10"/><text>topiramate</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="38" length="10"/><text>olanzapine</text></annotation></passage></document>
<document><id>22122406</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>As even the lower OTC dose of ibuprofen (150 mg) was enough to affect the antiplatelet effect of aspirin, health professionals should take into account patients</text><annotation id="0"><infon key="type">DrugName</infon><location offset="30" length="9"/><text>ibuprofen</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="97" length="7"/><text>aspirin</text></annotation></passage></document>
<document><id>20363700</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In conclusion our data indicate that concurrent use of morphine with buspirone may produce good cancer pain control and attenuate development of tolerance.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="55" length="8"/><text>morphine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="69" length="9"/><text>buspirone</text></annotation></passage></document>
<document><id>19050415</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Therefore, clinicians should be aware of the potentially severe adverse reactions that might occur during concomitant treatment with fluvoxamine and topiramate.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="133" length="11"/><text>fluvoxamine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="149" length="10"/><text>topiramate</text></annotation></passage></document>
<document><id>20720132</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We found that memantine blocks extrasynaptic NMDAR-mediated currents induced by bath application of 100 microM NMDA/10 microM glycine with a twofold higher potency than its blockade of the NMDAR component of evoked EPSCs (EPSCs(NMDAR)); this effect persists under conditions of pathological depolarization in the presence of 1 mm extracellular Mg(2+).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="14" length="9"/><text>memantine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="126" length="7"/><text>glycine</text></annotation></passage></document>
<document><id>21150631</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Caudal clonidine at a lower dose (1 µg kg?¹) could be effective in reducing the incidence of sevoflurane-induced emergence agitation in children undergoing urogenital and lower limb surgery without any significant adverse effects.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="19" length="9"/><text>clonidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="105" length="11"/><text>sevoflurane</text></annotation></passage></document>
<document><id>21842171</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Intraoperative reversal of shallow rocuronium-induced block with either sugammadex or neostigmine is an efficient method.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="47" length="10"/><text>rocuronium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="98" length="11"/><text>neostigmine</text></annotation></passage></document>
<document><id>21796940</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Ondansetron HCl was found to antagonize the wicking action of glycine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="62" length="7"/><text>glycine</text></annotation></passage></document>
<document><id>22924732</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS AND CLINICAL RELEVANCE: Results indicated GFR decreased after 8 days of concurrent administration of furosemide and carprofen or furosemide and etodolac to dogs.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="141" length="10"/><text>furosemide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="156" length="8"/><text>etodolac</text></annotation></passage></document>
<document><id>19175856</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We find that microtubule depolymerization in the SCN using either Colcemid or nocodazole enhances the efficacy of 10 pm melatonin to phase-shift the activity rhythms of the Long Evans rat.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="78" length="10"/><text>nocodazole</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="120" length="9"/><text>melatonin</text></annotation></passage></document>
<document><id>19322074</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>This study suggests that the haloperidol-induced interoceptive drug state is directly involved in its antiavoidance action, and chlordiazepoxide may attenuate the antiavoidance efficacy of antipsychotics (especially olanzapine).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="128" length="16"/><text>chlordiazepoxide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="216" length="10"/><text>olanzapine</text></annotation></passage></document>
<document><id>19455620</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>These results are in contrast to previous reports that the sulfonamide-based ERA bosentan can cause marked decreases in the exposure of tadalafil.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="81" length="8"/><text>bosentan</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="136" length="9"/><text>tadalafil</text></annotation></passage></document>
<document><id>19928382</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In rat synaptosomes, nomifensine reduced the potency of amphetamine to induce DA release approximately 270-fold, potentially explaining its action in ameliorating amphetamine-induced RHS.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="21" length="11"/><text>nomifensine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="163" length="11"/><text>amphetamine</text></annotation></passage></document>
<document><id>21878578</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Naltrexone was given to block the opioid effects of fentanyl.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="10"/><text>naltrexone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="52" length="8"/><text>fentanyl</text></annotation></passage></document>
<document><id>23305678</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>These data suggest that nalbuphine attenuates the development of sensitization to the behavioral effects of cocaine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="24" length="10"/><text>nalbuphine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="108" length="7"/><text>cocaine</text></annotation></passage></document>
<document><id>22005021</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The MT-Mla and the M(1) antagonist pirenzepine caused a dose-dependent block on total [(3)H]inositol phosphate accumulation induced by carbachol.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="35" length="11"/><text>pirenzepine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="135" length="9"/><text>carbachol</text></annotation></passage></document>
<document><id>21264118</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Because concomitant administration of gliclazide with provastatin and gemfibrozil in diabetes is associated with atherosclerosis, it should be contraindicated or used with caution.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="38" length="10"/><text>gliclazide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="70" length="11"/><text>gemfibrozil</text></annotation></passage></document>
<document><id>22401777</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Suggestions for clinical trials are provided for oral high-dose dextromethorphan and Nuedexta (dextromethorphan combined with quinidine to block metabolism to dextrorphan, thereby increasing dextromethorphan plasma concentrations).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="126" length="9"/><text>quinidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="191" length="16"/><text>dextromethorphan</text></annotation></passage></document>
<document><id>19469000</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Nicotine enhances the migration and invasion of the esophageal squamous carcinoma cell line, and nimesulide partly blocks the effect of nicotine-enhanced esophageal squamous carcinoma cell migration and invasion.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="148" length="8"/><text>nicotine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="109" length="10"/><text>nimesulide</text></annotation></passage></document>
<document><id>20655942</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Also, starch unexpectedly conditioned the stronger flavor preference, although this can be explained by the differential post-oral reinforcing actions of starch and sucrose, and naltrexone blocked the expression, but not the acquisition, of this preference.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="165" length="7"/><text>sucrose</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="178" length="10"/><text>naltrexone</text></annotation></passage></document>
<document><id>23153194</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: RSVL treatment increased the cytotoxic activity of DOX against the growth of human breast cancer cells when given either simultaneously or 24 h before DOX.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="12" length="4"/><text>RSVL</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="63" length="3"/><text>DOX</text></annotation></passage></document>
<document><id>22015717</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>These effects of guanfacine were blocked by co-administered yohimbine, a non-selective a(2)-AR antagonist.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="17" length="10"/><text>guanfacine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="60" length="9"/><text>yohimbine</text></annotation></passage></document>
<document><id>21400007</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Diosmin inhibits platelet aggregation and prolongs the effect of norepinephrine on venous tone, leading to increased venoconstriction.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="7"/><text>diosmin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="78" length="14"/><text>norepinephrine</text></annotation></passage></document>
<document><id>23217055</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="22"/><text>adenosine A2A receptor</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="122" length="10"/><text>vancomycin</text></annotation></passage></document>
<document><id>19465360</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Chronic low-dose oral amiodarone attenuates the proarrhythmic effects of dobutamine, increasing the safety of ambulatory IDI.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="35" length="10"/><text>amiodarone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="86" length="10"/><text>dobutamine</text></annotation></passage></document>
<document><id>23458202</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Quercetin administered to pregnant diabetic rats controlled dyslipidemia and improved lipid profiles in diabetes mellitus, regulated oxidative stress by reducing the generation of lipid hydroperoxides, and increased the activity of the antioxidant enzyme glutathione peroxidase.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="9"/><text>quercetin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="255" length="22"/><text>glutathione peroxidase</text></annotation></passage></document>
<document><id>20716624</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Using zebrafish embryos as the model, we demonstrate that morphine decreases miR-133b expression, hence increasing the expression of its target, Pitx3, a transcription factor that activates tyrosine hydroxylase and dopamine transporter.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="58" length="8"/><text>morphine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="215" length="8"/><text>dopamine</text></annotation></passage></document>
<document><id>23318138</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>20-O-ß-d-glucopyranosyl-20(S)-protopanaxadiol, a metabolite of ginseng, inhibits colon cancer growth by targeting TRPC channel-mediated calcium influx.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="49" length="21"/><text>metabolite of ginseng</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="136" length="7"/><text>calcium</text></annotation></passage></document>
<document><id>20573081</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>This phase I trial in healthy subjects investigated the bronchodilator activity of aclidinium and its ability to reduce methacholine-induced bronchoconstriction.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="83" length="10"/><text>aclidinium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="120" length="12"/><text>methacholine</text></annotation></passage></document>
<document><id>19873537</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>One interpretation of the findings is that caffeine reduces the binding of calcium both in the membrane and in the myoplasm; this increases the "permeability" to calcium and the ionic activity of calcium in muscle.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="43" length="8"/><text>caffeine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="196" length="7"/><text>calcium</text></annotation></passage></document>
<document><id>23079899</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: In an animal model of PCP-induced cognitive impairment, cariprazine pretreatment significantly diminished PCP-triggered cognitive deficits, and studies on knockout mice show that dopamine D(3) receptors contribute to this effect.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="69" length="11"/><text>cariprazine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="119" length="3"/><text>PCP</text></annotation></passage></document>
<document><id>21762772</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Clomipramine is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine by indirect actions on the dopaminergic system and LHPA axis.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="12"/><text>clomipramine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="87" length="14"/><text>norepinephrine</text></annotation></passage></document>
<document><id>19010609</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Considered together, this pattern of findings demonstrates that bupropion decreases responding for methamphetamine, but the effects are only somewhat specific.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="64" length="9"/><text>bupropion</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="99" length="15"/><text>methamphetamine</text></annotation></passage></document>
<document><id>19242981</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Our results suggest that sertraline may reduce the membrane conduction through inhibition of ionic channels which decrease ouabain-induced arrhythmia.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="25" length="10"/><text>sertraline</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="123" length="7"/><text>ouabain</text></annotation></passage></document>
<document><id>19164462</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>On the other hand, 1 microM cimetidine at the basolateral side moderately decreased the basolateral-to-apical transport of [(14)C]metformin and significantly increased the intracellular accumulation of [(14)C]metformin from the basolateral side, suggesting that cimetidine at a low concentration inhibits apical hMATE1, rather than basolateral hOCT2.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="262" length="10"/><text>cimetidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="209" length="9"/><text>metformin</text></annotation></passage></document>
<document><id>22001099</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Darifenacin, oxybutynin, tolterodine, and solifenacin (1 µM) all significantly depressed the frequency responses to carbachol (1 µM).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="42" length="11"/><text>solifenacin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="116" length="9"/><text>carbachol</text></annotation></passage></document>
<document><id>20522968</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The morphine-induced increase in OA-sensitive PP activity was dependent on the dose and attenuated by the concurrent administration of naloxone (1 mg/kg).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="4" length="8"/><text>morphine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="135" length="8"/><text>naloxone</text></annotation></passage></document>
<document><id>22480387</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Our findings further support the hypothesis that the synergistic effect of olanzapine and fluoxetine on prefrontal cortical levels of norepinephrine and dopamine might be an underlying mechanism for the efficacy of olanzapine-fluoxetine combination in the treatment of treatment-resistant depression and, if replicated, may form a basis on which response to olanzapine-fluoxetine combination versus continued fluoxetine can be predicted based on variants in SLC6A2.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="371" length="10"/><text>olanzapine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="422" length="10"/><text>fluoxetine</text></annotation></passage></document>
<document><id>19073220</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The results showed that bilateral but not unilateral intra-VTA administration of lidocaine significantly decreases the acquisition (P&lt;0.01) and expression (P&lt;0.05) of morphine-induced CPP compared to their respective saline-microinjected groups.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="81" length="9"/><text>lidocaine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="167" length="8"/><text>morphine</text></annotation></passage></document>
<document><id>22973962</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In aggregate, these data show the ability of crizotinib to specifically target CSC-like-subpopulations, interfere with cell-proliferation, induce apoptosis, reduce migration and synergistically interact with gemcitabine, supporting further studies on this novel therapeutic approach for PDAC.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="45" length="10"/><text>crizotinib</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="208" length="11"/><text>gemcitabine</text></annotation></passage></document>
<document><id>21051660</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Dexrazoxane is a cardioprotectant that significantly reduces the incidence of adverse cardiac events in women with advanced breast cancer treated with doxorubicin-containing regimens.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="11"/><text>dexrazoxane</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="151" length="11"/><text>doxorubicin</text></annotation></passage></document>
<document><id>19542104</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Our study demonstrated that the combination treatment of two different analgesic modalities, alfentanil and lidocaine, could prevent the moderate and severe pain on propofol injection, and reduce the incidence of mild pain compared with each drug alone.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="106" length="10"/><text>alfentanil</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="121" length="9"/><text>lidocaine</text></annotation></passage></document>
<document><id>19838586</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Data have shown that hyperprolactinemia induced by metoclopramide determines endometrial proliferation and interferes with the ovarian function, mainly in the progesterone production.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="64" length="14"/><text>metoclopramide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="172" length="12"/><text>progesterone</text></annotation></passage></document>
<document><id>19398092</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>RESULTS: The highest dose of estradiol in combination with progesterone was associated with the most pronounced symptom recurrence, both in comparison with a lower dose of estradiol together with progesterone and estradiol-only treatment.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="213" length="9"/><text>estradiol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="196" length="12"/><text>progesterone</text></annotation></passage></document>
<document><id>23044721</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Our analysis suggests that prophylaxis with peg-filgrastim may considerably reduce the incidence of grade 3 or more neutropenia and, possibly, of febrile neutropenia in mCRPC patients treated with cabazitaxel.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="44" length="14"/><text>peg-filgrastim</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="197" length="11"/><text>cabazitaxel</text></annotation></passage></document>
<document><id>20300828</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Results demonstrate that metformin significantly decreases the forskolin/phorbol ester (FSK/PMA)-induced expression of aromatase at concentrations of 10 and 50 muM.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="25" length="9"/><text>metformin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="63" length="9"/><text>forskolin</text></annotation></passage></document>
<document><id>19491681</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In contrast, higher systemic progestin levels associated with the use of depot medroxyprogesterone acetate and combination oral contraceptives suppress ovarian estradiol production and reduce acquisition of BMD in teenagers and young adult women who use injectable and oral contraceptives.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="79" length="27"/><text>medroxyprogesterone acetate</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="160" length="9"/><text>estradiol</text></annotation></passage></document>
<document><id>21300952</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="27" length="12"/><text>eptifibatide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="205" length="11"/><text>clopidogrel</text></annotation></passage></document>
<document><id>21240617</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Tocilizumab treatment increased the activity of factor VIII in a rapid and sustained manner, leading to a reduction of the prednisolone dose.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="11"/><text>tocilizumab</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="48" length="11"/><text>factor VIII</text></annotation></passage></document>
<document><id>19450656</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Using the intranigral lipopolysaccharide (LPS) rat model, we show that meloxicam, a preferential COX-2 inhibitor, diminishes the activation of OX-42-immunoreactive (ir) microglia and reduces the loss of tyrosine hydroxylase (TH)-ir dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) that is normally induced by exposure to LPS.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="22" length="18"/><text>lipopolysaccharide</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="71" length="9"/><text>meloxicam</text></annotation></passage></document>
<document><id>22502642</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Adenosine A2A receptor activation and hyaluronan fragment inhibition reduce inflammation in mouse articular chondrocytes stimulated with interleukin-1ß.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="38" length="10"/><text>hyaluronan</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="137" length="14"/><text>interleukin-1ß</text></annotation></passage></document>
<document><id>21940785</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Celecoxib can be used effectively and safely to prevent capecitabine-related HFS.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="9"/><text>celecoxib</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="69" length="12"/><text>capecitabine</text></annotation></passage></document>
<document><id>21232049</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Nicotine treatment (0.4 mg·kg?¹·da?¹, 10 days) increased more than 100-fold the potency of bPiDI (IC50=1.45 nM) to inhibit nicotine-evoked dopamine release.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="8"/><text>nicotine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="91" length="5"/><text>bPiDI</text></annotation></passage></document>
<document><id>19298689</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>An increase in the dose of quinine may be necessary when the drug is co-administered with nevirapine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="27" length="7"/><text>quinine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="90" length="10"/><text>nevirapine</text></annotation></passage></document>
<document><id>23084637</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>A recent study reported that resveratrol directly inhibits cyclic adenosine monophosphate-specific phosphodiesterases and then activates 5</text><annotation id="0"><infon key="type">DrugName</infon><location offset="29" length="11"/><text>resveratrol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="59" length="58"/><text>cyclic adenosine monophosphate-specific phosphodiesterases</text></annotation></passage></document>
<document><id>19966835</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Our results suggest that aspirin inhibits the proliferation of gemcitabine-resistant pancreatic cancer cells and augments the antisurvival effect of gemcitabine, probably by suppressing the activity of GSK-3beta and its downstream gene products.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="37" length="7"/><text>aspirin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="161" length="11"/><text>gemcitabine</text></annotation></passage></document>
<document><id>23024850</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>DISCUSSION: Addition of magnesium lidocaine in patients undergoing upper extremity orthopedic operations using IVRA decreases significantly the time gap between drug administration and the start of the block; also, this drug combination increases the IVRA block length, while paracetamol does not have such a significant effect.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="24" length="9"/><text>magnesium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="34" length="9"/><text>lidocaine</text></annotation></passage></document>
<document><id>20004658</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Finally, the noradrenalin transporter together with dopamine transporter blocker bupropion was more effective in decreasing the stress of an injection in SERT(-/-) rats than in SERT(+/+) rats.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="24"/><text>noradrenalin transporter</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="81" length="9"/><text>bupropion</text></annotation></passage></document>
<document><id>19501616</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The attenuation of mossy fiber LTP by tail suspension was completely restored when rats were pretreated with clioquinol (30 mg/kg) to block the action of chelatable zinc.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="109" length="10"/><text>clioquinol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="165" length="4"/><text>zinc</text></annotation></passage></document>
<document><id>22475804</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Ethanol abuse was associated with >50% lower cumulative dose of morphine equivalents (ratio 0.47; 95% CI 0.25-0.87).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="7"/><text>ethanol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="64" length="8"/><text>morphine</text></annotation></passage></document>
<document><id>20814282</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: The addition of dexamethasone to mepivacaine prolongs the duration of analgesia but does not reduce the onset of sensory and motor blockade after ultrasound-guided supraclavicular block compared with mepivacaine alone.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="29" length="13"/><text>dexamethasone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="213" length="11"/><text>mepivacaine</text></annotation></passage></document>
<document><id>23474678</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>MEASUREMENTS AND MAIN RESULTS: Our study demonstrates that 1) proteasomal glucocorticoid receptor degradation is established in brain endothelial cells after traumatic brain injury as a form of posttranslational glucocorticoid receptor modification; 2) inhibition of the proteasomal degradation pathway with bortezomib (0.2 mg/kg) in combination with the glucocorticoid dexamethasone (10 mg/kg) by subcutaneous injection 30 minutes postinjury restores levels of barrier sealing glucocorticoid receptor target occludin in brain endothelial cells, improves blood-brain barrier integrity, reduces edema formation, and limits neuronal damage after brain trauma.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="308" length="10"/><text>bortezomib</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="370" length="13"/><text>dexamethasone</text></annotation></passage></document>
<document><id>22341836</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Low doses of oxybutynin, an anticholinergic medication that competitively antagonizes the muscarinic acetylcholine receptor, can be used to treat palmar hyperhidrosis with fewer side effects.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="10"/><text>oxybutynin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="101" length="22"/><text>acetylcholine receptor</text></annotation></passage></document>
<document><id>23475371</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Selenium attenuates adriamycin-induced cardiac dysfunction via restoring expression of ATP-sensitive potassium channels in rats.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="0" length="8"/><text>selenium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="20" length="10"/><text>adriamycin</text></annotation></passage></document>
<document><id>22457863</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Randomized, double-blind studies demonstrated the effectiveness of neostigmine, which increases cholinergic tone, combined with glycopyrrolate, an anticholinergic agent with minimal activity in the colon that reduces extracolonic side-effects.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="67" length="11"/><text>neostigmine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="128" length="14"/><text>glycopyrrolate</text></annotation></passage></document>
<document><id>19039973</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>As the TOFR was 1.44 when the surgery completed, the trachea was extubated without giving neostigmine to antagonize the effect of vecuronium.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="90" length="11"/><text>neostigmine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="130" length="10"/><text>vecuronium</text></annotation></passage></document>
<document><id>19119629</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Genistein can reduce the expression of TGF-beta1 and block the accumulation of intracellular free calcium induced by growth factors.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="13" length="9"/><text>genistein</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="111" length="7"/><text>calcium</text></annotation></passage></document>
<document><id>19664616</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Following the administration of long-acting risperidone a constant ability to antagonize amphetamine-induced hyperlocomotion was observed during the day, but not when the antipsychotic was chronically administered using a short-acting formulation.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="44" length="11"/><text>risperidone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="89" length="11"/><text>amphetamine</text></annotation></passage></document>
<document><id>21965742</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Resveratrol works in concert with antiandrogen flutamide to reduce the amount and activity of AR, suggesting new therapeutic strategies for the treatment of PCa.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="12" length="11"/><text>resveratrol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="59" length="9"/><text>flutamide</text></annotation></passage></document>
<document><id>23424217</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The synergistic actions of clonazepam and tiagabine gave enhanced seizure protection and reduced toxicity, suggesting that combination therapy may be well tolerated and effective for seizures in DS.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="27" length="10"/><text>clonazepam</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="42" length="9"/><text>tiagabine</text></annotation></passage></document>
<document><id>21585521</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>These data suggest that melatonin improves the beneficial effects of atorvastatin and reduces its side effects in endothelial cells during inflammation and under conditions of oxidative stress.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="24" length="9"/><text>melatonin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="69" length="12"/><text>atorvastatin</text></annotation></passage></document>
<document><id>23332768</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="7" length="12"/><text>methotrexate</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="68" length="13"/><text>ciprofloxacin</text></annotation></passage></document>
<document><id>22547332</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Based upon the in vitro results, pioglitazone reduces N-methyl-D-aspartate (NMDA)-mediated calcium currents in hippocampal neurons.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="33" length="12"/><text>pioglitazone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="54" length="20"/><text>N-methyl-D-aspartate</text></annotation></passage></document>
<document><id>19919585</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: Magnesium sulphate given 15 min before propofol anaesthesia reduces the onset time of rocuronium by about 35% and prolongs the total recovery time by about 25%.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="12" length="18"/><text>magnesium sulphate</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="98" length="10"/><text>rocuronium</text></annotation></passage></document>
<document><id>19789949</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSIONS: Prophylactic pyridoxine and urea ointment at first appearance of symptoms appears to reduce the risk of severe capecitabine-induced HFS.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="26" length="10"/><text>pyridoxine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="124" length="12"/><text>capecitabine</text></annotation></passage></document>
<document><id>21396983</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Collectively, the present data suggest that intrathecal melatonin attenuates the facilitated state and acute pain evoked by formalin injection.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="56" length="9"/><text>melatonin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="124" length="8"/><text>formalin</text></annotation></passage></document>
<document><id>23085073</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In conclusion, aripiprazole-augmented treatment might be beneficial for the metabolic regulation of patients being treated with a stable dose of olanzapine, but not for those treated with other atypical antipsychotics.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="15" length="12"/><text>aripiprazole</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="145" length="10"/><text>olanzapine</text></annotation></passage></document>
<document><id>19653517</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>It is concluded that abdominal surgery may be associated with statistically significant changes in heart rate in isoflurane-anaesthetised pigs and that the combined administration of epidural ropivacaine may prevent statistically significant changes in HR during abdominal surgery.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="113" length="10"/><text>isoflurane</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="192" length="11"/><text>ropivacaine</text></annotation></passage></document>
<document><id>23544168</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Both inhibitors augmented the response to doxorubicin, suggesting that clinical responses likely will be improved using both drugs in combination; however, dasatinib was significantly (P &lt; .05) more effective in this context.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="42" length="11"/><text>doxorubicin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="156" length="9"/><text>dasatinib</text></annotation></passage></document>
<document><id>22902499</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>KEY FINDINGS: Both nAChR and mAChR antagonists (hexamethonium and methacine, respectively), per se, elevated histamine-releasing activity of the HMC-1 and suppressed the MC responses to most of investigated activators (carbachol, compound 48/80, and to a lesser extent aIgG).</text><annotation id="0"><infon key="type">DrugName</infon><location offset="48" length="13"/><text>hexamethonium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="219" length="9"/><text>carbachol</text></annotation></passage></document>
<document><id>23371914</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>At a neuronal level, lithium reduces excitatory (dopamine and glutamate) but increases inhibitory (GABA) neurotransmission; however, these broad effects are underpinned by complex neurotransmitter systems that strive to achieve homeostasis by way of compensatory changes.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="21" length="7"/><text>lithium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="49" length="8"/><text>dopamine</text></annotation></passage></document>
<document><id>21896143</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>In general, the combined use of spironolactone and adequate doses of a thiazide diuretic or a thiazide-like agent such as chlorthalidone for the treatment of resistant hypertension maximizes efficacy and reduces the risk of spironolactone-induced hyperkalemia.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="122" length="14"/><text>chlorthalidone</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="224" length="14"/><text>spironolactone</text></annotation></passage></document>
<document><id>22138350</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>When the mice were treated with KXS (350 mg/kg, p.o) or desipramine (30 mg/kg, p.o) for 7 days, both of them could antagonize reserpine-induced ptosis, akinesia and hypothermia.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="56" length="11"/><text>desipramine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="126" length="9"/><text>reserpine</text></annotation></passage></document>
<document><id>19656263</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>When Gbetagamma downstream signalling was blocked by intra-PAG co-administration of 2-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)cyclohexane-1-carboxylic acid, a compound that inhibits Gbetagamma dimer-dependent signaling, a complete prevention of low dose morphine induced acute thermal hyperalgesia was obtained.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="5" length="10"/><text>gbetagamma</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="84" length="67"/><text>2-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)cyclohexane-1-carboxylic acid</text></annotation></passage></document>
<document><id>22658980</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Moreover, high-dose (0.5 mg/kg), but not low-dose (0.03 mg/kg), prazosin significantly attenuated citalopram (10 mg/kg)-induced decreases in conditioned freezing.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="64" length="8"/><text>prazosin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="98" length="10"/><text>citalopram</text></annotation></passage></document>
<document><id>20488096</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Some of the calcium-antagonist actions of nifedipine may be mediated by adenosine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="42" length="10"/><text>nifedipine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="72" length="9"/><text>adenosine</text></annotation></passage></document>
<document><id>21674180</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Using published in vitro data on the dependence of the percentage of apoptosis induced by the anti-cancer drug topotecan in a leukaemia cell line on the concentration of added caffeine, and a general model of competitive binding in a system containing two aromatic drugs and DNA, it has been shown to be possible to quantify the relative change in the biological effect just using a set of component concentrations and equilibrium constants of the complexation of the drugs.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="111" length="9"/><text>topotecan</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="176" length="8"/><text>caffeine</text></annotation></passage></document>
<document><id>19839966</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The increased retention in the dexamphetamine group, together with the general decreases in methamphetamine use, degree of dependence and withdrawal symptom severity, provide preliminary evidence that this may be an efficacious treatment option for methamphetamine dependence.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="31" length="14"/><text>dexamphetamine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="249" length="15"/><text>methamphetamine</text></annotation></passage></document>
<document><id>20884632</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>We found that adverse effects of doxorubicin were attenuated by acute or chronic treatment with the AT1 receptor antagonist losartan, which is commonly used to reduce blood pressure.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="33" length="11"/><text>doxorubicin</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="124" length="8"/><text>losartan</text></annotation></passage></document>
<document><id>20599502</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The ability of AC loaded zinc-pectinate beads to selectively decrease the intestinal residual fraction of ciprofloxacin could provide a better protection of the intestinal microbiota and may prevent the emergence of ciprofloxacin resistance in the gastrointestinal tract.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="25" length="4"/><text>zinc</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="216" length="13"/><text>ciprofloxacin</text></annotation></passage></document>
<document><id>19052508</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>PURPOSE: Salmeterol xinafoate (salmeterol) and fluticasone propionate (FP) combination (SFC) was reported to enhance improvement of lung function compared with concurrent administration of the two drugs from separate devices.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="31" length="10"/><text>salmeterol</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="47" length="22"/><text>fluticasone propionate</text></annotation></passage></document>
<document><id>19955429</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Finally, we find that administration of celecoxib to dogs interferes with the ability of a low dose of aspirin to inhibit AA-induced ex vivo platelet aggregation.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="40" length="9"/><text>celecoxib</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="103" length="7"/><text>aspirin</text></annotation></passage></document>
<document><id>20097580</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: The protective mechanism of NO on the vasoconstrictor effects of phenylephrine in the kidney is lost during the development of diabetes, probably via the actions of ROS through a decrease in tetrahydrobiopterin, thus contributing to the pathogenesis of diabetic nephropathy.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="40" length="2"/><text>NO</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="77" length="13"/><text>phenylephrine</text></annotation></passage></document>
<document><id>22737655</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>CONCLUSION: This study provides initial evidence for a drug-anesthetic interaction between ketamine and isoflurane that is very different from responses to a-chloralose-ketamine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="104" length="10"/><text>isoflurane</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="169" length="8"/><text>ketamine</text></annotation></passage></document>
<document><id>22985391</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>When 2% lidocaine and 0.75% ropivacaine are used for a combined sciatic nerve-lumbar plexus block by 'staged' injection, lidocaine induced faster onset times, decreased the block duration and increased the AUC and C(max) of ropivacaine.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="8" length="9"/><text>lidocaine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="28" length="11"/><text>ropivacaine</text></annotation></passage></document>
<document><id>22900583</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>These data demonstrate that ritonavir is able to block prasugrel CYP3A4 bioactivation.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="28" length="9"/><text>ritonavir</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="55" length="9"/><text>prasugrel</text></annotation></passage></document>
<document><id>19872456</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>The addition of sodium or potassium ions produces a marked decrease in the effect of magnesium diions on the activity of oxalate diions.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="26" length="9"/><text>potassium</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="85" length="9"/><text>magnesium</text></annotation></passage></document>
<document><id>23277819</id><passage><infon key="DDI">Yes</infon><offset>0</offset><text>Though a combination of dexmedetomidine and remifentanil may not prevent the hemodynamic instability impeccably during the tumor manipulation, this combination seems to be the way of interrupting release of catecholamines and minimizing hemodynamic fluctuations.</text><annotation id="0"><infon key="type">DrugName</infon><location offset="24" length="15"/><text>dexmedetomidine</text></annotation><annotation id="1"><infon key="type">DrugName</infon><location offset="44" length="12"/><text>remifentanil</text></annotation></passage></document>
</collection>
